Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study

Coates, L, Mease, P, Gladman, D et al. (8 more authors) (2019) Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study. In: 2019 ACR/ARP Annual Meeting Minutes, 08-13 Nov 2019, Atlanta, Georgia, USA.

Metadata

Authors/Creators:
  • Coates, L
  • Mease, P
  • Gladman, D
  • Van den Bosch, F
  • Rychlewska-Hanczewska, A
  • Tasset, C
  • Meuleners, L
  • Trivedi, M
  • Gao, J
  • Besuyen, R
  • Helliwell, P
Keywords: Janus kinase (JAK), OLE and filgotinib, Psoriatic arthritis
Dates:
  • Published: 29 October 2019
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 09 Nov 2020 15:25
Last Modified: 09 Nov 2020 16:05
Status: Published
Identification Number: https://doi.org/10.1002/art.41108
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics